AHL Partners LLP increased its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 0.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 89,919 shares of the company’s stock after acquiring an additional 424 shares during the quarter. AHL Partners LLP owned about 0.37% of USANA Health Sciences worth $5,764,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Renaissance Technologies LLC boosted its position in USANA Health Sciences by 10.6% during the second quarter. Renaissance Technologies LLC now owns 1,948,266 shares of the company’s stock worth $124,884,000 after acquiring an additional 186,600 shares during the last quarter. FMR LLC boosted its position in USANA Health Sciences by 3.9% during the second quarter. FMR LLC now owns 1,598,143 shares of the company’s stock worth $102,441,000 after acquiring an additional 60,033 shares during the last quarter. Vanguard Group Inc. boosted its position in USANA Health Sciences by 2.6% during the second quarter. Vanguard Group Inc. now owns 979,726 shares of the company’s stock worth $62,801,000 after acquiring an additional 25,136 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in USANA Health Sciences by 2.3% during the second quarter. Dimensional Fund Advisors LP now owns 710,918 shares of the company’s stock worth $45,570,000 after acquiring an additional 15,748 shares during the last quarter. Finally, Schroder Investment Management Group boosted its position in USANA Health Sciences by 9.0% during the second quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock worth $36,734,000 after acquiring an additional 47,448 shares during the last quarter. Hedge funds and other institutional investors own 44.87% of the company’s stock.

A number of equities analysts recently weighed in on the stock. BidaskClub lowered shares of USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research report on Monday, July 31st. Pivotal Research lowered their price target on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Wednesday, July 26th.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/06/ahl-partners-llp-acquires-424-shares-of-usana-health-sciences-inc-usna.html.

USANA Health Sciences, Inc. (NYSE USNA) opened at 58.05 on Friday. The company’s 50-day moving average is $57.83 and its 200-day moving average is $60.11. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 15.08 and a beta of 1.09. USANA Health Sciences, Inc. has a 52-week low of $52.55 and a 52-week high of $75.00.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.08). USANA Health Sciences had a net margin of 9.47% and a return on equity of 28.93%. The business had revenue of $257.10 million for the quarter, compared to analysts’ expectations of $273.61 million. During the same quarter last year, the business posted $2.07 earnings per share. The business’s revenue was down .5% compared to the same quarter last year. Equities analysts predict that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.

USANA Health Sciences announced that its board has initiated a stock buyback program on Tuesday, July 25th that permits the company to buyback $64.60 million in outstanding shares. This buyback authorization permits the company to purchase up to 46% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

In other USANA Health Sciences news, COO Jim Brown sold 16,574 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $58.84, for a total transaction of $975,214.16. Following the sale, the chief operating officer now directly owns 2,175 shares of the company’s stock, valued at approximately $127,977. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel A. Macuga sold 5,751 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $60.00, for a total transaction of $345,060.00. Following the sale, the insider now directly owns 2,077 shares in the company, valued at $124,620. The disclosure for this sale can be found here. Insiders have sold a total of 386,340 shares of company stock valued at $22,270,913 over the last 90 days. 53.20% of the stock is currently owned by insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.